临床试验/NCT06182410

NCT06182410撤回2 期

Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy in Patients With High-Risk Neuroblastoma Receiving Tandem Transplants

University of California, San Francisco0 个研究点开始时间: 2024年8月1日最近更新: 2024年8月7日

适应症

干预措施

试验速览

阶段: 2 期
状态: 撤回
发起方: University of California, San Francisco
主要终点: Cumulative incidence of transplant-associated thrombotic microangiopathy (TA-TMA)

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

This phase II trial tests how well defibrotide works in preventing transplant-associated thrombotic microangiopathy (TA-TMA) in patients with high-risk neuroblastoma undergoing tandem transplants (hematopoietic stem cell transplant [HSCT]). TMA is a potential life-threatening complication of stem cell transplant. TMA is a possible side effect of the chemotherapy (conditioning regimen) patients receive to help treat high-risk neuroblastoma, because these medicines can sometimes damage the blood vessel walls in the body. This damage leads to formation of tiny blood clots in organs, especially the kidney. This then causes organ damage and leads to problems with how they function. This study may help researchers learn how defibrotide may help prevent TMA before it starts, or help treat it once it starts among patients with high-risk neuroblastoma undergoing tandem transplants.

详细描述

PRIMARY OBJECTIVE:

I. To determine if administration of prophylactic defibrotide sodium (defibrotide) will prevent the development of TA-TMA in participants with high-risk neuroblastoma receiving tandem transplants compared to historic controls.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of defibrotide in the prevention of severe TA-TMA, as defined by any TA-TMA with one or more of the following complications:

Ia. Renal failure requiring dialysis; Ib. Pleural or pericardial effusion requiring any surgical intervention; Ic. Central nervous system dysfunction, including seizure, posterior reversible encephalopathy syndrome (PRES); Id. Pulmonary hypertension; Ie. Biopsy-proven gastrointestinal involvement with bleeding; If. Death not related to relapse of underlying neuroblastoma; II. To determine the incidence of grade ≥ 3 hemorrhage (per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) in participants on prophylactic defibrotide (grade 3 hemorrhage = transfusion indicated; invasive intervention indicated; hospitalization).

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Supportive Care
盲法: None

入排标准

年龄范围: 1 Year 至 18 Years（Child, Adult）
性别: All
接受健康志愿者: 否

入选标准

•Age: 1 - < 18 years old.
•Participants must have high-risk neuroblastoma according to Children's Oncology Group (COG) risk classification at the time of initial diagnosis. Participants who were initially considered low or intermediate risk, but then reclassified as high risk are also eligible.
•Participants may have had salvage therapies (i.e., meta-iodobenzylguanidine (MIBG), dinutuximab) after induction but cannot have progressive disease at start of
•Planned tandem transplants with conditioning with cyclophosphamide-thiotepa and carboplatin-etoposide-melphalan on, or as per, NCT03126916 (ANBL1531) or other tandem-containing COG high-risk neuroblastoma trials.
•Participants may be enrolled in upfront neuroblastoma protocol, but this is not required.
•Upfront MIBG or other therapies is not a contraindication.
•Organ function per institutional standard of care (SOC) guiding clearance for autologous HSCT.
•Written informed consent (and assent when applicable) obtained from participant or participant's legal representative and ability for subject to comply with the requirements of the study.

排除标准

•Life expectancy < 6 months.
•Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
•Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
•Known bleeding diathesis or bleeding risk deemed by the treating physician to be a contraindication to administration of defibrotide or on concomitant therapeutic anticoagulation. Administration of heparin and/or alteplase for central line maintenance is allowed.

研究组 & 干预措施

Supportive Care (defibrotide)

Experimental

Participants receive defibrotide IV over 2 hours every six hours on days -8 to +21 during the first and second rounds of Hematopoietic stem-cell transplantation (HSCT).

干预措施: Defibrotide (Drug)

结局指标

主要结局

Cumulative incidence of transplant-associated thrombotic microangiopathy (TA-TMA)

时间窗: Up to1 year

The cumulative incidence of TA-TMA in participants will be compared to historical controls. The historic controls will be participants with high-risk neuroblastoma who underwent planned tandem transplant at University of California San Francisco (UCSF) between 2017 and 2023.

次要结局

Cumulative incidence of severe TA-TMA(Up to 1 year)

研究者

发起方

University of California, San Francisco

申办方类型

Other

责任方

Sponsor

相似试验

进行中（未招募）

2 期

Itacitinib for the Prevention of Graft Versus Host DiseaseHematologic and Lymphocytic Disorder

NCT04859946M.D. Anderson Cancer Center31

终止

2 期

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell TransplantChronic Graft Versus Host DiseaseHematopoietic and Lymphatic System Neoplasm

NCT06271616Mayo Clinic2

已完成

2 期

Defibrotide in COVID-19 PneumoniaPatients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure

NCT04335201IRCCS San Raffaele50

撤回

2 期

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell TransplantationAllogeneic Stem Cell Transplant RecipientHematologic and Lymphocytic DisorderHematopoietic and Lymphoid Cell Neoplasm

NCT04127721M.D. Anderson Cancer Center

已完成

2 期

NCT00089011Fred Hutchinson Cancer Center150